Hem Securities report on Caplin Point
Total Revenue stood at Rs 312.02 Cr for Q2FY22, registering a growth of 15.6% over Q2FY21. PAT increased by 22.3% to Rs. 76.82 Cr in Q2FY22. Gross Margins improved by 345bps to 58.6% in Q2FY22. Free Cash Flow stood at Rs. 103 Cr for H1FY22. Company receives approval from Brazil’s ANVISA for injectable plant through mutual recognition of US FDA EIR. CRO wing Amaris Clinical completes back-to-back virtual and physical USFDA audits, both with NIL observation.
We expect company to deliver topline growth of 20% over next few years. We recommend to ACCUMULATE the stock with price target of Rs. 896.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.